BOSTON/Massachusetts, TORONTO/Canada, March 3 /PRNewswire/ - BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry, have jointly announced an exclusive worldwide collaboration and agreement to discover and develop new therapeutics for unmet needs in ophthalmology.
Dalton Medicinal Chemistry will utilize their proprietary insights to advance several novel classes of compounds against selected BIKAM targets. BIKAM will advance these agents with their cutting edge battery of biological assays and delivery methodologies.
David Garvey, VP, Chemistry at BIKAM commented: "We are pleased to have the opportunity to work with the creative team at Dalton Medicinal Chemistry in the discovery and development of new entities for treating eye diseases. Their expertise, together with our propriety and leading position will quickly deliver important new medicines."
Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to have this opportunity to work with BIKAM in the discovery and development of much needed agents to treat these debilitating diseases".
BIKAM, Inc., is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of degenerative eye diseases and disorders. BIKAM is building a portfolio of product candidates based on patented technologies that were identified at the University of Florida, Gainesville. BIKAM investors include HealthCare Ventures, CHL Medical Partners and Fidelity Biosciences.
About Dalton Pharma Services & Dalton Medicinal Chemistry
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a
Health Canada contract pharmaceutical manufacturer that supplies chemistry
and analytical services to the biotechnology and pharmaceutical industries
in the areas of chemistry and fine chemical manufacture. Dal
|SOURCE Dalton Pharma Services|
Copyright©2008 PR Newswire.
All rights reserved